MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • MDS Virtual Congress 2021

    Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial

    D. Pourzinal, A. Bakker, G. Byrne, K. Mcmahon, J. O'Sullivan, R. Adam, A. Lehn, D. Copland, J. Yang, G. Pontone, T. Au, R. Littleford, M. Chatfield, Z. Mari, N. Dissanayaka (Herston, Australia)

    Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…
  • MDS Virtual Congress 2021

    The effect of medical xenon on patients with advanced stages of the Parkinson’s disease with motor fluctuations

    R. Bogdanov, E. Vasilchenko, A. Dobrovolsky, P. Ratmanova, D. Napalkov, V. Bogin (Moscow, Russian Federation)

    Objective: The aim of the study to increase the effectiveness of pharmacotherapy in patients with advanced stages of Parkinson's disease (PD) with motor fluctuations, using…
  • MDS Virtual Congress 2021

    Survey-Based study of marijuana used in Parkinson’s Disease patients

    R. Healy, J. Paulson, A. Deb, K. Smith (Worcester, USA)

    Objective: A survey based assessment of marijuana use in patients with Parkinson’s disease. Background: Due to marijuana’s controlled status little quality research and no clear…
  • MDS Virtual Congress 2021

    Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

    B. Mohamed, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Cardiff, United Kingdom)

    Objective: This post-hoc analysis evaluated the influence of baseline demographic characteristics (i.e., age and gender) on the response to opicapone (OPC) in Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory lockdown and its management with the help of Telemedicine in a North Indian cohort

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To study problems faced by PD patients during lockdown due lack of healthcare and medication procurement and address such problems using telemedicine via virtual…
  • MDS Virtual Congress 2021

    Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial

    JR. Zhang, JP. Chen, J. Li, J. Li, CJ. Mao, CF. Liu (Suzhou, China)

    Objective: This study, an open-labeled trial, was aimed to assess the efficacy and safety of selegiline on the treatment of EDS in PD patients. Background: Excessive Daytime…
  • MDS Virtual Congress 2021

    Could Gender have an effect on Clinical and Transcranial Parenchymal Ultrasound Findings in Parkinson’s disease Patients?

    R. Soliman, N. Kishk, M. Oraby, A. Alsayyad, M. Abdel Salam, M. Abo Srea (Cairo, Egypt)

    Objective: We aimed to explore the possible differences between males and females as regarding motor, non-motor, depressive symptoms, cognitive functions and Transcranial Parenchymal Ultrasound (TCS)…
  • MDS Virtual Congress 2021

    Parkinson’s disease patients may be at higher risk of Covid-19 mortality

    M. Salari, M. Etemadifar, S. Tehrani Fateh, Z. Aminzade (Tehran, Islamic Republic of Iran)

    Objective: To investigate the Covid-19 mortality in Parkinson’s disease (PD) patients. Background: PD patients may be at increased risk of Covid-19 mortality due to the…
  • MDS Virtual Congress 2021

    NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson’s Disease

    L. Gibson, T. Pollak, M. Hart, D. Trivedi, T. Nicholson, M. Zandi, K R. Chaudhuri, D. Aarsland (London, United Kingdom)

    Objective: To quantify the frequency of NMDA receptor (NMDAR) antibodies (Abs) in Parkinson’s disease (PD) and characterise their relationship with the cognitive and neuropsychiatric symptoms.…
  • MDS Virtual Congress 2021

    Falls in Parkinson’s Disease: The Impact of Cognitive Performance

    F. Rolim, A. Gomes, V. Santos, D. Torres, F. Carvalho (Fortaleza, Brazil)

    Objective: This study aimed to assess the incidence of falls in a population of PD patients and their clinical performance on cognitive assessment scales. Background:…
  • « Previous Page
  • 1
  • …
  • 431
  • 432
  • 433
  • 434
  • 435
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley